Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

Clinical trial NCT04634825 · TERMINATED

Trial details

NCT number: NCT04634825
Sponsor: MacroGenics
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Cancer Head and Neck Neoplasms Head and Neck Squamous Cell Carcinoma

Start date: 2021-03-17
Primary completion: 2022-07-29
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.